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Abstract 
We present a comprehensive review of research conducted in our laboratory in pursuit of the 
long-term goal of reproducing the structures and reactivity of carboxylate-bridged diiron centers 
used in biology to activate dioxygen for the conversion of hydrocarbons to alcohols and related 
products.  This article describes the evolution of strategies devised to achieve these goals and 
illustrates the challenges in getting there.  Particular emphasis is placed on controlling the 
geometry and coordination environment of the diiron core, preventing formation of polynuclear 
iron clusters, maintaining the structural integrity of model complexes during reactions with 
dioxygen, and tuning the ligand framework to stabilize desired oxygenated diiron species.  
Studies of the various model systems have improved our understanding of the electronic and 
physical characteristics of carboxylate-bridged diiron units and their reactivity toward molecular 
oxygen and organic moieties.  The principles and lessons that have emerged from these 
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investigations will guide future efforts to develop more sophisticated diiron protein model 
complexes. 
Keywords: carboxylate-bridged diiron modeling, dioxygen activation, biomimetic chemistry, 
ligand design 
 
1. Introduction 
 Understanding the role of metal ions in dictating protein structure and function is a 
central theme in bioinorganic research [1-4].  In addition to the arsenal of modern physical 
techniques and instrumentation available for studies of biomolecules [5], synthetic modeling has 
been pursued as a complementary method for understanding complex biological systems [6].  It 
provides a convenient simplification of elaborate macromolecules in a real, rather than a virtual, 
computational, platform [7].  By reducing a metalloprotein to its functional core, it is possible to 
learn the extent to which the chemistry that occurs at the metal center is predominantly a result 
of the inorganic component or a consequence of the protein complex as a whole.  Synthetic 
modeling also provides an opportunity to access chemistry that has not yet been achieved using 
simple biological building blocks under ambient conditions.  Some of the most remarkable 
transformations in nature, such as nitrogen fixation [8-11], water splitting [12], and hydrogen 
production [13], are performed by metalloenzymes under physiological conditions. Reproducing 
such chemical reactivity in an efficient manner has the potential not only to revolutionize the 
chemical industry but also to provide new sustainable sources of energy [14].  Finally, the 
synthetic challenges of modeling chemistry will push the limits of current synthetic 
methodology.  Although natural product synthesis has been largely aided by an understanding of 
organic chemistry [15], inorganic synthesis is not governed by the same set of well-defined rules 
	   3 
[16].  Nature works at a kilohertz and requires, in many cases, first-row transition metals as 
active sites for catalysis.  Controlling the kinetic stability and resultant nuclearity of metal 
centers using organic ligands comprises the single significant challenge in bioinorganic modeling 
chemistry.  
Small-molecule metalloprotein mimics are prepared using one of two design strategies 
[4].  The biomimetic approach seeks to duplicate the active site structure as faithfully as possible, 
particularly in matching the identity and geometric arrangement of ligands in the primary 
coordination sphere.  The bio-inspired approach, on the other hand, only requires that the 
synthetic model shares some common features with those of the protein core, unrestricted by the 
type or position of ligands coordinated to the metal center.  For modeling studies, the former is 
preferred over the latter because biomimetic complexes more accurately reproduce the 
characteristics of the biological center under investigation.  
1.1. Carboxylate-Bridged Diiron Proteins 
 Carboxylate-bridged diiron proteins are involved in essential physiological processes [17, 
18].  Although their roles vary, the first step in their respective reaction mechanisms involves 
binding and activation of dioxygen.  In hemerythrin (Hr) [19], the O2 molecule coordinates to a 
single iron site and acquires two electrons and a proton to generate a (hydroperoxo)diiron(III) 
unit (Scheme 1, top).  This process is reversible and is the basis for O2 transport in some marine 
invertebrates.  Unlike hemerythrin, ribonucleotide reductase (RNR) [20] and bacterial multi-
component monooxygenases (BMMs) [21] consume dioxygen to perform catalytic reactions 
(Scheme 1, middle and bottom, respectively).  Activation of O2 by these enzymes leads to 
formation of (peroxo)diiron(III) or di(µ-oxo)diiron(IV) complexes that are capable of oxidizing 
organic moieties [22-26]. The high-valent diiron intermediate in the R2 subunit of RNR 
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generates a tyrosyl radical that ultimately initiates the first step in DNA biosynthesis, conversion 
of ribo- to deoxyribonucleotides, whereas that in the hydroxylase component of the BMMs is 
responsible for inserting an oxygen atom into the C–H bond of hydrocarbon substrates.  The 
most well-studied member of the BMM family is soluble methane monooxygenase (sMMO) 
[27], which is unique for its ability to hydroxylate methane to methanol.  Recent studies have 
revealed that other classes of enzymes containing carboxylate-bridged diiron motifs also exist in 
biology [28-30]. 
These diiron proteins contain two iron atoms that are coordinated by imidazole and 
carboxylate residues, where at least one of the carboxylate groups bridges the two metal centers 
[17].  The structural similarities between the active sites of this protein family indicate that their 
functional differences are derived from variations in their Asp/Glu/His amino acid combinations 
and/or careful tuning of their tertiary and quaternary protein structures.  Discerning factors that 
may contribute to their mechanism of action is an important goal in synthetic model studies [31, 
32].  
The following is a chronological account of the strategies and tactics employed in our 
laboratory to prepare structural and functional mimics of diiron protein active sites.  This work 
has evolved a rational basis for ligand design based on the findings that resulted from studies of 
the various model systems.  The reader is referred elsewhere for more general reviews of 
synthetic modeling of carboxylate-bridged diiron proteins [31-36]. 
 
2. Ligand Platforms 
2.1. Mononucleating, Polydentate N-Heterocyclic Ligands 
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  The first successful attempt to prepare a mimic of the diiron core in Hr was achieved 
using hydrotris(pyrazolyl)borate (TP–) (Table 1) [37, 38], a tripodal ligand widely employed in 
transition metal chemistry.  Reaction of TP–, iron(III), and acetate led to the spontaneous self-
assembly of [FeIII2(µ-O)(µ-CH3CO2)2(TP)2] (1), the structure of which closely matches that of 
metHr, the inactive form of Hr [19].  Reaction of 1 with an H+ donor led to formation of 
[FeIII2(µ-OH)(µ-CH3CO2)2(TP)2]+ (2), a stable protonated analogue of 1 [39].  Spectroscopic and 
magnetic measurements of the (µ-oxo)di(µ-carboxylato)diiron(III) and (µ-hydroxo)di(µ-
carboxylato)diiron(III) compounds provided valuable benchmarks for identifying such units in 
biology [40, 41].  When 1 was exposed to H218O, the 16O bridge was readily exchanged for 18O, 
indicating that of the inability to exchange water into the protein is due to inaccessibility of H2O 
to the diiron core rather than an intrinsic property of the {FeIII2O}4+ unit. An undesirable feature 
of 1 and 2 is that the facially capping nature of the TP– ligands does not allow for open 
coordination sites, which are required for O2 binding . Moreover, reduction of the diiron(III) 
species resulted in irreversible dissociation to monoiron complexes [38].  
 To access the asymmetric diiron center in Hr, the denticity of the capping ligand was 
reduced from three to two by using bis(1-methylimidazol-2-y1)phenylmethoxymethane 
(BIPhMe) (Table 1) [42, 43].  Stirring iron(II) formate with BIPhMe in methanol provided 
[FeII2(µ-HCO2)3(HCO2)(BIPhMe)2] (3).  X-ray crystallography revealed a dinuclear structure 
with both five- and six-coordinate iron sites, in which each metal ion is bound by a BIPhMe 
ligand and bridged by three formate groups.  A terminal acetate group completes the 
coordination sphere of the six-coordinate iron atom.  Complex 3 reacts instantaneously with 
dioxygen to give [FeIII2(µ-O)(µ-HCO2)2(HCO2)2(BIPhMe)2] (4), with no detectable 
intermediates.  Manometric measurements indicated that 0.5 equiv of O2 are consumed per 
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diiron(II) complex, suggesting that 4 is formed via a tetranuclear dioxygen species.  The 
behavior of 3 toward dioxygen is different from that of deoxyHr, however, which binds O2 
reversibly (Scheme 1, top) [19].  
2.2. Dicarboxylate Ligands 
 To increase the structural integrity of the carboxylate-bridged diiron center, several 
dicarboxylate ligands were explored as dinucleating platforms.  The first of these, m-
phenylenedipropionate (MPDP2-, Table 1) [44, 45], was selected because the distance between 
its β-methylene carbon atoms matches the 6 Å separation between acetate methyl carbon atoms 
in [FeIII2(µ-O)(µ-CH3CO2)2(TP)2] (1) [37].  The use of MPDP2– facilitated the synthesis of 
[FeIII2(µ-O)(MPDP)(bpy)2Cl2] (5) (bpy = 2,2’-bipyridine) and [FeIII2(µ-O)(MPDP)(BIPhMe)2Cl2] 
(6, Table 1), complexes that could not be obtained from self-assembly using two equivalents of 
simple monocarboxylate anions.  The cyclic voltammogram of [FeIII2(µ-O)(MPDP)(TP)2] (7), an 
analogue of 1, showed that mononuclear [FeII(TP)2] and [FeIII(TP)2]+ species are generated upon 
electrochemical reduction and oxidation, respectively.  Thus, linking the carboxylate groups 
using MPDP2– does not impart the desired additional stability.  
 To obtain a more robust bridging framework, m-xylenediamine bis(Kemp’s triacid)imide 
(XDK2–, Table 1), a compound devised for molecular recognition in organic chemistry [46, 47], 
was employed.  The rigid conformation of the carboxylate units in XDK2– provides a well-
defined cleft for assembly of homo- and heterodimetallic complexes [48-51].  A diiron(III) 
compound, [FeIII2(µ-O)(XDK)(CH3OH)5(H2O)](NO3)2 (8), was readily prepared from iron(III) 
nitrate and XDK2– [52].  Kinetic studies of the substitution of coordinated solvents in 8 by either 
2,2´-bipyridine or N-methylimidazole suggested that anion binding and exchange at the active 
site of hemerythrin proceed with rates similar to those exhibited by small-molecules and that the 
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protein scaffold does not alter the intrinsic rate of terminal ligand exchange at the diiron center. 
Preparation of a series of pseudohalide-bound diiron(III) compounds of the formula [FeIII2(µ-
O)(XDK)(bpy)2(X)2], where X = NCS–, NCSe–, or N3–, facilitated detailed studies of the 
spectroscopic signatures of molecules with terminal ligation to carboxylate-bridged diiron units 
[53].  A notable discovery was the appearance of only one asymmetric 15NNN– stretch in the 
azide derivative; apparently this spectroscopic feature is not sufficient to discount the possibility 
of a terminally coordinated azide group because isotopically shifted peaks may be too close to 
one another in energy to be resolved.  
 The XDK2– ligand also supports carboxylate-bridged diiron(II) units having the general 
composition [FeII2(XDK)(µ-RCO2)(RCO2)(N-donor)2], where R = t-Bu- (pivalate), PhCy- (1-
phenylcyclohexylcarboxylate), Ph- (benzoate), iPr- (isobutyrate), or tBuCH2- (1-tert-
butylacetate);  N-donor = py (pyridine), 3-Fpy (3-fluoropyridine), N-MeIm (N-methylimidazole), 
or N-tBuIm (N-tert-butylimidazole) [54-56].  More sterically hindered XDK2– variants, 
containing either propyl (PXDK2–) or benzyl (BXDK2–)in place of methyl substituents on the 
Kemp’s triacid moiety, could also be employed to assemble similar diiron(II) compounds.  The 
asymmetric bridging mode of the ancillary carboxylate to the diiron(II) core is determined by 
both steric and electronic factors [56].  X-ray structural studies suggested that greater steric 
repulsion between XDK2– and the external carboxylate, and more basic N-donors, favor a 
syn,syn-bidentate bridging mode of the ancillary carboxylate rather than a syn,anti-monodentate 
one.  For complexes having sufficiently bulky groups, such as [FeII2(XDK)(µ-
PhCyCO2)(PhCyCO2)(py)2] (9, Table 1), exposure to O2 led to formation of stable peroxo 
adducts at low temperature [56].  Although these (peroxo)diiron(III) species could not be 
crystallized for X-ray diffraction studies, resonance Raman measurements indicated that the 
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dioxygen molecule is bound in a µ-1,2 fashion.  Reactivity studies of the {FeIII2(O2)}4+ units 
revealed that they are nucleophilic [57], rather than electrophilic like the oxygenated 
intermediates in the BMMs [58, 59].  When warmed above -65°C, the {FeIII2(O2)}4+ species 
rapidly decayed, initiating a radical chain pathway that oxidized solvents with weak to 
intermediate C–H bond strengths.  Despite having the same ligand stoichiometry as that of the 
(peroxo)diiron(III) species in sMMOH (Hperoxo) and related enzymes [27], the synthetic 
analogues do not reproduce the substrate scope, product selectivity, and probably the reaction 
mechanism of the diiron monooxygenases.  It is possible that the doubly bridging XDK2– ligand 
in the synthetic models is too rigid to allow an Hperoxo-like structure to be generated, a likely 
prerequisite for attaining the high oxidizing power of the diiron protein oxygenated 
intermediates. 
 A continued search for a ligand that is sufficiently pre-organized yet structurally flexible 
led to examination of other dicarboxylate motifs.  One potential candidate is the dibenzofuran-
4,6-bis(diphenylacetate) dianion (Ph4DBA2-, Table 1) [60, 61].  As in XDK2–, Ph4DBA2– has two 
orthogonal carboxylate groups that can support an {FeIII2O}4+ core.  The Ph4DBA2– ligand, 
however, has more conformational freedom than XDK2– because the C–C bonds linking the 
carboxylate groups to the dibenzofuran unit can rotate freely.  The compound [FeII2(µ-
OH)(Ph4DBA)(TMEDA)2(CH3CN)]+ (10, Table 1), where TMEDA = N,N,N´,N´-
tetramethylethylenediamine, was prepared from Ph4DBA2–, triethylamine, TMEDA, and iron(II) 
triflate.  The structure of 10 is unique because it is the first synthetic complex to reproduce the 
(µ-hydroxo)di(µ-carboxylato)diiron(II) core of deoxyHr [19], having an open coordination site 
for binding of a terminal ligand.  When 10 was treated with dioxygen at -78 °C in the presence of 
3 equiv of N-MeIm in CH2Cl2 or in neat EtCN, a red-orange species (11) appeared that decayed 
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after ~10 min.  The UV-visible (UV-vis), Mössbauer, resonance Raman, and EXAFS spectra of 
the transient intermediate closely match those of oxyHr (Scheme 1, top), strongly suggesting that 
11 contains a (hydroperoxo)(µ-oxo)diiron(III) unit.  Unlike Hr, however, oxygenation of 10 is 
irreversible and leads to decomposition to form a tetrairon(III) cluster.  
 A fourth dicarboxylate ligand, α,α-5,15-bis(α-N-(Kemp’s triacid imido)-o-tolyl)-
2,8,12,18-tetraethyl-3,7,13,17-tetramethylporphyrin (PDK4–, Table 1), was prepared by replacing 
the m-xylenediamine linker of XDK2– with a porphyrin unit [62].  The construct was designed 
such that activation of O2 within a trimetallic cavity would offer the possibility of supplying 
additional electrons to the carboxylate-bridged diiron centers, much like the reductase 
component of sMMO [27].  A triiron(II) compound, [FeII3(PDK)(Lut)(Br)2(HBr)] (12, where Lut 
= 2,6-lutidine, Table 1), was successfully prepared following metallation with iron(II) bromide 
[63].  When iron(II) chloride was used instead of iron(II) bromide in the preparation, a mixed-
valent heptairon chloride cluster was isolated [64].  Owing to the complicated nature of the iron 
complexes of PDK4–, no further studies were pursued using this ligand.  
 The more pre-organized dicarboxylate ligands XDK2– and Ph4DBA2– impart enhanced 
stability to their respective diiron complexes and allow detection of O2 adducts at low 
temperature.  A common problem with the dicarboxylate ligands, however, is that they do not 
prevent aggregation of the metal complexes into oligo- and polynuclear clusters [65], an 
undesired reaction that is detrimental to the synthesis of accurate models.  Furthermore, the 
conformationally rigid ligand framework may be a liability in terms of accessing oxygenated 
diiron species that could further react with external substrates. During the reaction cycle of many 
non-heme diiron enzymes, “carboxylate shifts,” or changes in the binding mode of carboxylate 
units to the diiron centers [66], are required for catalysis [67, 68].  Thus, devising a motif that 
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incorporates such “flexible” carboxylate groups into a ligand framework is an important 
synthetic goal. 
2.3. Terphenylcarboxylate Ligands  
 To reduce the geometric constraints of the ligand platform, bulky terphenylcarboxylates 
were employed.  Unlike simple benzoates that form polynuclear clusters with iron [69-71], the 
sterically hindered 2,6-bis(p-tolyl)benzoate (ArTolCO2–, Table 1) and 2,6-bis(p-
fluorophenyl)benzoate (Ar4-FPhCO2–) ligands promote the self-assembly of discrete diiron 
compounds in the presence of iron salts and an appropriate base [72, 73].  The first iron complex 
synthesized in this series is [FeII2(µ-ArTolCO2)2(ArTolCO2)2(THF)2] (13, THF = tetrahydrofuran), 
which adopts a “windmill” structure with two syn,syn-bridging carboxylates and two bidentate 
terminal carboxylates in the solid-state.  The coordinated THF molecules in 13 can be readily 
substituted with N-donors to afford the corresponding [FeII2(ArTolCO2)4(N-donor)2] complex.  
Use of 4-tert-butylpyridine (4-tBuPy) as the ancillary base provided a quadruply bridged 
[FeII2(ArTolCO2)4(4-tBupy)2] (14A, Table 1) “paddlewheel” compound.  Interconversion between 
windmill (Scheme 2, 14C) and paddlewheel (Scheme 2, 14A) structures occurs in solution [66], 
as demonstrated by variable temperature NMR spectroscopic studies [73].  Oxygenation of 14A 
at -78°C resulted in irreversible formation of a deep green intermediate that decayed to a 
[FeIII2(µ-OH)2(µ-ArTolCO2)2(ArTolCO2)2(4-tBupy)2] (17) product [74, 75].  The di(µ-
hydroxo)diiron(III) unit of 17 closely resembles that of the oxidized core of sMMOH [76].  
Characterization of the green intermediate revealed two mixed-valent complexes, a diiron(II,III) 
(15) and a diiron(III,IV) (16) species, that are present in equal amounts.  EPR and magnetic 
Mössbauer measurements indicated that 15 and 16 have spin states of 9/2 and 1/2, respectively.  
The assignment of 15 as a diiron(II,III) compound was confirmed by comparing its spectroscopic 
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properties to those of a crystallographically characterized [FeIIFeIII(ArTolCO2)4(4-tBupy)2]+ 
complex [77, 78].  As shown in the mechanism proposed in Scheme 2, reaction of 14A with 
dioxygen proceeds through a carboxylate shift, in which either one or two of the bridging 
ArTolCO2– groups rearrange to adopt terminal positions, providing an open site for O2.  Binding 
of dioxygen to 14B or 14C affords a (µ-peroxo)diiron(III) or a di(µ-oxo)diiron(IV) intermediate 
that further reacts with 14A, giving an equal mixture of 15 and 16.  This reaction is noteworthy 
because it provides the first example for a synthetic model compound in which treatment of a 
diiron(II) precursor with O2 resulted in formation of an iron(IV) species, a process that parallels 
the chemistry of several carboxylate-bridged diiron enzymes [17].  Oxygenation of diiron 
complexes derived from other terphenylcarboxylate ligand variants, such as 2,6-
bis(mesityl)benzoate or 2,6-bis(dimethylbenzyl)-4-tert-butylbenzoate, have yielded 
(peroxo)diiron(III) species with distinct spectroscopic signatures.  A detailed comparison of 
these latter systems with those studied in our laboratory is available [79].  
 Although the steric hindrance provided by the terphenycarboxylates could suppress 
undesired reactions involving bond-making processes, it could not eliminate deleterious 
intermolecular electron transfer (ET) reactions [74, 75].  To prevent the paddlewheel diiron(II) 
complex from quenching the oxygenated intermediates, bidentate ancillary ligands were used to 
favor the assembly of windmill rather than paddlewheel species.  The doubly-bridged [FeII2(µ-
ArTolCO2)2(ArTolCO2)2(N,N-Bn2en)2] (18) complex, where N,N-Bn2en = N,N-
dibenzylethylenediamine, was prepared to test this strategy [80, 81].  Compound 18 reacted with 
dioxygen, but instead of producing a green intermediate, N-dealkylation occurred affording 
[FeIII2(µ-OH)2(µ-ArTolCO2)(ArTolCO2)3(N-Bnen)(N,N-Bn2en)] (19) (where N-Bnen = N-
benzylethylenediamine) and benzaldehyde.  Isotopic labeling with 18O2 demonstrated that the 
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oxygen atom in benzaldehyde was derived from O2.  When a non-coordinating N,N-Bn2en 
analogue, such as N,N-dibenzylpropylamine, was treated with O2 in the presence of either 
mononuclear or dinuclear iron(II) complexes, the yield of benzaldehyde was significantly 
reduced.  Detailed mechanistic studies suggested that oxidative N-dealkylation of 18 involves 
single electron transfer, proton abstraction, and rearrangement [82, 83].  This fortuitous 
discovery that high-valent diiron terphenylcarboxylate complexes could be intercepted by 
tethered substrates inspired subsequent studies of the reactivity of oxygenated intermediates 
toward organic moieties held in close proximity to the diiron center.  Attachment of benzyl [84, 
85], ethyl [85], ethynyl [86], phenoxyl [87], phosphido [84, 88], or sulfido [88, 89] units to an 
amine or pyridine ligand afforded a series of tethered substrates that could be easily incorporated 
into 13, affording the corresponding diiron(II) compounds.  After exposing the 
substrate/diiron(II) complex to O2, the reaction products were analyzed by gas chromatography-
mass spectrometry (GC-MS).  Chart 1 depicts substrates that were successfully oxidized by this 
method.  When 2-pyridyldiphenylphosphine (2-Ph2Ppy) was employed in excess, catalytic 
oxidation to 2-pyridyldiphenylphosphine oxide (2-Ph2P(O)py) was observed [84, 88].  Because 
external non-coordinating substrates cannot be oxidized by [Fe2(ArTolCO2)4(THF)2]/O2, these 
results suggest that intramolecular reactions are preferred over intermolecular ones in the 
terphenylcarboxylate diiron complexes.  This behavior is most likely of the consequence of the 
formation of an active diiron oxidant that can react with solvent or adventitious reductants before 
being intercepted by the desired external substrates. 
 One strategy to prevent premature deactivation of an oxygenated diiron intermediate was 
to attach dendritic groups to the terphenylcarboxylate ligand to shield the diiron core from 
participating in intermolecular ET reactions [90].  The complex [FeII2([G-3]CO2)4(4-CNpy)2] 
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(20) (where [G-3]CO2– = third-generation dendrimer-appended terphenylcarboxylate and 4-
CNpy = 4-cyanopyridine) was synthesized in a manner analogous to that for the simpler 
diiron(II) compounds.  Treatment of 20 with dioxygen resulted in formation of a diiron(II,III) 
intermediate that was postulated to have a superoxo ligand.  This colored intermediate is capable 
of oxidizing dihydroanthracene, albeit in only modest yields of up to ~40%. 
 The influence of water on the structure and reactivity of the diiron(II) terphenyl-
carboxylate compounds was also examined. Treatment of 14A with excess water afforded a 
diaqua-bridged diiron(II) species, [FeII2(µ-H2O)2(µ-ArTolCO2)2(ArTolCO2)2(4-tBupy)2] (21), in 
which the terminal carboxylates exhibit strong hydrogen-bonding interactions with the bridging 
waters [91].  In addition to having a diaqua bridge, a third H2O molecule occupies a terminal 
position in [FeII2(µ-H2O)2(µ-Ar4-FPhCO2)(Ar4-FPhCO2)3(THF)2(H2O)] (22) [92].  When a large 
excess of water was added to 22, complete dissolution occurred, giving the fully aquated 
[FeII(H2O)6]2+ cation. These observations suggest that the accessibility of water within diiron 
enzyme active sites may be a control element for achieving different functions using a common 
structural motif.  The presence of excess amounts of water may be destructive to the integrity of 
the carboxylate-bridged diiron core, however.  Stopped-flow kinetic studies using [FeII2(µ-
ArTolCO2)4(4-CNpy)2] (23) showed that it reacts with H2O ~1000 times faster than with O2 and 
that aquated 23 reacts with O2 ~10 times faster than anhydrous 23 [93, 94].  Coordination of 
water to 23 most likely induces rearrangement from a paddlewheel to a windmill geometry, 
facilitating more rapid binding of dioxygen to the diiron center. 
  The iron chemistry of a variety of other monocarboxylate ligands was evaluated.  When 
the steric bulk of the terphenylcarboxylate was increased using 2,6-bis(p-(tert-butyl)phenyl)-
benzoate (ArtBuCO2–), reaction with iron(II) salts afforded a tetrairon cluster [95].  When the 
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steric demand of the carboxylate was reduced using 2-biphenylcarboxylate, an assortment of di-, 
tri-, and tetranuclear species was obtained [96].  Replacing the terphenylcarboxylate with 9-
triptycenecarboxylate resulted in diiron paddlewheel complexes that could not convert to the 
more reactive windmill structure [97].  
 Terphenylcarboxylate ligands are a simple alternative to the conformationally restricting 
dicarboxylate compounds.  Diiron complexes derived from ArTolCO2– or Ar4-FPhCO2– can access 
high valent iron(IV) species from O2, which are capable of hydroxylating hydrocarbons, a first 
for synthetic modeling studies.  Although the 2,6-aryl substituents of ArTolCO2– and Ar4-FPhCO2– 
are effective in shielding against metal cluster assembly, they also contribute to excessive steric 
crowding at the diiron core, which prevents facile entry of external substrates. 
2.4. Dinucleating Polynitrogen Ligands 
 Polydentate nitrogen donors are commonly utilized as ligands in synthetic modeling 
studies [31, 98].  Although these compounds provide a nitrogen-, rather than a carboxylate-rich 
coordination environment they are well suited for stabilizing kinetically labile first row transition 
metal ions.  Efforts to mimic the syn, syn coordination of the bridging carboxylate in the active 
site of diiron enzymes led to use of a naphthyridine framework as a “masked carboxylate” [99].  
Several 1,8-substituted naphthyridine compounds were prepared and successfully employed to 
assemble dicopper(II), dizinc(II), dinickel(II), and diiron(II) complexes [100].  The most notable 
of these are [FeII2(µ-OH)(BPEAN)(SO3CF3)]2+ (24, where BPEAN = 2,7-bis(bis(2-(2-(5-
methyl)pyridyl)ethyl)aminomethyl)-1,8-naphthyridine, Table 1) and [FeII2(µ-
OH)(BEPEAN)(SO3CF3)]2+ (25, where BEPEAN = 2,7-bis(bis(2-(2-(5-ethyl)pyridyl)-
ethyl)aminomethyl)-1,8-naphthyridine) [101]. Exposing either 24 or 25 to O2 at room 
temperature resulted in rapid decomposition without any detectable intermediates.  When the 
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more sterically hindered 25 was treated with excess hydrogen peroxide at -30 °C a red-brown 
species (26) appeared, which decayed upon warming to room temperature.  Spectroscopic 
characterization of 26 suggested that it is a (hydroperoxo)diiron(III) species.  The decay of 26 is 
accompanied by O2 evolution and formation of a diiron(II) unit, the identity of which is different 
from that of 25.  Although the mechanism of this reaction is uncertain, the release of O2 from 26 
may mimic a process similar to that in hemerythrin. 
 The stability of the diiron(II) naphthyridine compounds afforded an opportunity to 
investigate how the redox properties of the model complexes vary depending on their 
composition and structure.  Because activation of O2 in the diiron enzymes invariably results in 
oxidation of the metal center, knowledge of the redox potential of the diiron(II) models may  
help to explain their dioxygen reactivity.  The cyclic voltammogram of [FeII2(BPMAN)(µ-
PhCyCO2)2]2+ (27, where BPMAN = 2,7-bis(bis(2-pyridylmethyl)aminomethyl)-1,8-
naphthyridine) displayed two reversible redox waves at +296 and +681 mV (vs. 
ferrocene/ferrocenium) attributed to two one-electron oxidation processes, of diiron(II,II) to 
diiron(II,III) and diiron(II,III) to diiron(III,III), respectively [102].  The presence of two 
reversible metal-centered redox couples was unprecedented for diiron(II) compounds not having 
single atom bridge.  Comparing the first oxidation potential of 27 to that of [FeII2(ArTolCO2)4(4-
tBupy)2] (14A) (E1/2 = -216 mV) revealed that addition of each anionic carboxylate group lowers 
the redox potential of the diiron center by ~ 250 mV.  These results also suggested that diiron(II) 
sites bridged only by Asp and Glu residues in biology could supply up to two electrons without 
significant change in geometry. 
 Another polynitrogen donor compound, 1,4-bis(2,2ʹ -dipyridylmethyl)phthalazine (bdptz, 
Table 1), was explored as a potential dinucleating platform [103]. Reaction of bdptz with iron(II) 
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triflate and ArTolCO2– afforded a stable diiron(II) complex, [FeII2(µ-OH)(µ-ArTolCO2)(bdptz)-
(CH3CN)(SO3CF3)](SO3CF3) (28, Table 1).  Treatment of 28 with dioxygen instantaneously led 
to formation of a (µ-oxo)diiron(III) product, [FeIII2(µ-O)(µ-ArTolCO2)(bdptz)(acetone)(SO3CF3)]-
(SO3CF3)2 (29) with no detectable intermediates. A bulkier derivative of bdptz was prepared to 
block the possible formation of tetranuclear species, but no remarkable oxygenation chemistry 
was observed with the diiron complex of this compound [104]. 
 Although the napthryridine and phthalazine bridged diiron model complexes are 
structurally robust, they do not exhibit the same O2 reactivity observed in the diiron proteins.  
Perhaps polydentate ligands with internal bridging units are too rigid to accommodate binding of 
O2 to the diiron center. 
2.5. Syn N-Donor Ligands 
 An important structural feature that has been difficult to reproduce in carboxylate-bridged 
diiron model complexes is the syn coordination of nitrogen donors relative to the iron-iron vector 
(Scheme 1) [31].  Despite the different arrangement of carboxylate ligands within the active sites 
of the BMMs, RNR, and related enzymes, ligation of the two histidine residues always occurs 
with syn stereochemistry [17].  To enforce the syn arrangement of nitrogen donors within a 
single ligand framework, two quinoline ester moieties were covalently attached using a 
diethynylbenzene linker, giving 1,2-bis(3-ethynyl-8-carboxylatequinoline)-4,5-diethynylbenzene 
ethyl ester (Et2BCQEBEt, Table 1) [105].  Metallation of Et2BCQEBEt using iron(II) triflate and 
ArTolCO2– afforded the compound [FeII2(Et2BCQEBEt)(µ-ArTolCO2)3]+ (30, Table 1).  X-ray 
structural analysis of 30 revealed a diiron complex with three bridging carboxylates and syn 
binding of the quinoline moieties.  Although 30 is a close structural mimic of sMMOHred 
(Scheme 1, bottom) [76], exposing the compound to dioxygen resulted in iron products that 
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could not be identified.  Other neutral derivatives of Et2BCQEBEt were prepared and examined 
as syn N-donor ligands [106].  The compound bis(picolinic methyl ester)diethynyltriptycene 
(PIC2DET) containing pyridine methyl ester groups afforded a heterometallic 
[FeIINa(PIC2DET)(µ-TrpCO2)3] (31) complex that could exchange sodium for iron; the resulting 
diiron(II) compound could not be structurally characterized, however [107].  Two syn N-donor 
ligands can also bridge two iron(II) centers, giving [FeII2(syn N-donor)2] species [108].  Several 
examples are shown in Chart 2 [S. Friedle, L.H. Do, S.J. Lippard, Unpublished work].  Such 
undesired [FeII2(syn N-donor)2] species were avoided by the use of ligands bearing polydentate 
nitrogen-rich metal binding groups [109].  Only diiron(III) complexes, however, could be 
prepared from these ligands. 
 To obtain a kinetically more stabilizing platform, 2-phenoxylpyridine groups were 
attached to a 1,2-diethynylbenzene backbone [110].  Reaction of bis(phenyl(p-cresol)pyridyl)-
diethynylbenzene ([LMe,Ph]2–) with iron(II) in THF led to spontaneous formation of 
[FeII2(LMe,Ph)2(THF)3] (32D, Chart 2).  Once again, rotation about the C–C bond of the ethynyl 
arms allowed association of two syn N-donor ligands.  Unlike complex 30, however, reaction of 
32D with dioxygen resulted in the quantitative formation of a (µ-oxo)diiron(III) [FeIII2(µ-
O)(LMe,Ph)2] (33) product.  No intermediates were detected during the oxygenation reaction.  
 Several other ligand designs based on the syn N-donor concept were also explored.  An 
attempt was made to incorporate both a bridging carboxylate and adjacent amine moieties into a 
dinucleating platform using 1,8-bis(dimethylaminomethylethynyl)-3,6-di(tert-butyl)fluorene-9-
yl-acetate (DAFA2–, Table 1) [111].  Efforts to metallate DAFA2– with iron(II) were 
unsuccessful, possibly due to a lack of pre-organization among the amine and carboxylate donor 
groups of the ligand.  A two-component system was also proposed as a method to assemble 
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diiron(II) model complexes.  In addition to a syn N-donor, a “C-clamp” ligand with two endo-
oriented dicarboxylate groups may enforce a doubly-bridging motif and form a hydrophobic 
pocket around the diiron center [112].  Complexation reactions with a C-clamp and syn N-donor 
ligands have not yet afforded the desired [FeII2(syn N-donor)(C-clamp)] unit, however. 
 Linking two N-heterocycles with a 1,2-diethynylarene spacer effectively enforces the syn 
coordination of nitrogen donors in a diiron complex.  Because the compounds do not have an 
internal bridging group to link the two metal ions like other dinucleating ligands, their terminal 
metal-binding units must be sufficiently stabilizing to prevent dissociation of the dinuclear core.  
Additional ligand modifications are needed to eliminate the possibility of forming [FeII2(syn N-
donor)2] species. 
2.6. Macrocyclic Ligands 
 Macrocyclic ligands are excellent hosts for transition metal ions, as evident from 
numerous examples in biology [3, 4] as well as synthetic coordination chemistry [113, 114].  
Initial efforts to prepare a dinucleating macrocycle led to synthesis of a bis(terphenylcarboxylate) 
compound linked by 1,3-bis(aminomethyl)-4,6-diisopropylbenzene (MArTolCO22–, Table 1) 
[115].  The endo-carboxylate groups in MArTolCO22– were designed to bridge two iron atoms to 
form a pre-organized platform for binding of additional external ligands.  The failure to complex  
MArTolCO22– with iron, however, was attributed to either the flexibility of the ligand architecture 
or improper spacing provided by the phenylene linker.  
 An improved macrocyclic design was obtained with the compound PIM2– (Table 1), 
which contains two phenoxylimine metal binding units linked by diphenylsulfone and 
dibenzylether moieties [116].  Reaction of H2PIM, the protonated form of PIM2–, with 
[FeII2(2,4,6-trimethylphenyl)4] and sterically hindered carboxylic acid afforded di(µ-
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carboxylato)diiron(II) complexes in good yield.  Use of terphenylcarboxylic acid and 
triphenylacetic acid gave [FeII2(µ-ArTolCO2)2(PIM)] (34, Table 1)  and [FeII2(µ-Ph3CCO2)2(PIM)] 
(35), respectively.  X-ray structural analysis revealed that both compounds accurately mimic the 
active site structure of sMMOHred (Scheme 1, bottom) [76], including the asymmetric µ-η1,η1 
and µ-η1,η2 binding mode of carboxylates as well as the syn stereochemistry of nitrogen donors.  
When 34 was exposed to dioxygen, a mixture of (µ-oxo)diiron(III) [FeIII2(µ-O)(ArTolCO2)2(PIM)] 
(36) and di(µ-hydroxo)diiron(III) [FeIII2(µ-OH)2(ArTolCO2)2(PIM)] (37) species was isolated.  
Further treatment of 36 and 37 with excess water resulted in dimerization of the complexes to 
form tetranuclear [FeIII4(µ-OH)6(PIM)2(ArTolCO2)2] (38) species.  To eliminate this 
decomposition pathway, the PIM2– ligand could be modified with sterically more hindering 
groups at the para position of the phenolate (Scheme 3).  Having a more bulky platform would 
also allow smaller carboxylate ligands to be employed, which may facilitate dioxygen binding or 
substrate access to the diiron center.  Unlike other platforms that have been investigated to date, 
the planar nature of the macrocycle allows for steric tuning of the diiron complex without 
obstructing access to the dimetallic center.  
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3. Concluding Remarks 
  The early years of synthetic modeling of carboxylate-bridged diiron protein active sites 
in our laboratory were characterized by use of simple chelating ligands to prepare structural 
mimics.  Efforts to replicate the functional aspects of these proteins, however, required more 
elaborately designed ligands.  The search for an ideal synthetic platform is complicated by a 
number of factors, such as the need for ligands that can complex two iron atoms to afford the 
desired coordination geometry, tune the ligand steric properties to prevent unproductive 
decomposition of reactive oxygenated species, and develop short and convenient routes to target 
compounds in significant quantities.  Although there is no substitute for direct studies of 
biomolecules, the work described in this summary illustrates that investigations using synthetic 
mimics can provide insight into metallobiochemistry in ways that could not be achieved through 
other means. 
 Synthetic diiron modeling still offers many unexplored frontiers.  One area of interest is 
understanding the chemical nature as well as the requirements for generating potent oxidizing 
diiron units.  One strategy to access such chemically reactive species is to prepare diiron 
complexes that have optimally positioned functional groups to stabilize key transition states 
along the O2 reaction pathway. Identifying which transition state structures to target can be aided 
by the use of quantum mechanical calculations [117, 118].  This concept has been successfully 
demonstrated in de novo protein design [119-121], but has not yet been seriously applied to 
construct small-molecule protein models.  Use of outer sphere coordination to influence the 
reactivity of metallocenters is well documented in biology [122].  For example, recent studies of 
toluene/o-xylene monooxygenase hydroxylase (ToMOH), a member of the BMM family, 
suggest that a threonine residue in the second coordination sphere of the protein active site 
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facilitates formation of a (µ-η1,η1-hydroperoxo)diiron(III) species through proton transfer and 
hydrogen bonding to the coordinated dioxgyen ligand [123, 124].  This interaction, although 
subtle, may help explain why the (peroxo)diiron(III) intermediate of ToMOH has characteristics 
that are distinct from those of sMMOH.  Another avenue of research that would help advance 
diiron modeling chemistry is to establish a clear structure-function relationship between the 
model compounds and their oxygenation behavior [125].  For example, although it has been 
shown that exposing dioxygen to a synthetic diiron(II) complex can lead to formation of a 
(peroxo)diiron(III) species, this reactivity is not general to all diiron(II) model compounds.  In 
many cases, it is unclear whether oxygenated diiron units are not observed because they are 
rapidly quenched by external reactants, do not form under the experimental conditions employed, 
or the starting complexes are too sterically hindered to bind O2.  To evaluate the various factors 
that contribute to the dioxygen reactivity in a synthetic model, it is necessary to make systematic 
structural and electronic modifications to the complex.  Unfortunately, most model systems are 
not amenable to such investigations because the structural integrity of the complexes may be 
compromised upon introducing such changes.  Because PIM2– is a remarkably robust 
dinucleating platform and has many potential sites for derivatization, it is an excellent framework 
for such studies.  
Although this review has focused exclusively on diiron modeling chemistry in our 
laboratory, many other research groups have made significant contributions to the development 
of carboxylate-bridged diiron protein model complexes and the investigation of their chemical 
and physical characteristics.  A large number of synthetic platforms have been devised for the 
assembly of carboxylate-bridged diiron model complexes, ranging from simple 
carboxylate/pyridine [126] donors to tailored-made dinucleating ligands [31, 127] and synthetic 
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peptides [128, 129].  Although many of the diiron model compounds reported are structurally 
robust [31, 127], they do not capture the unique coordination sphere of the bioinorganic unit of 
interest.  Perhaps as a consequence of the incomplete match, the synthetic complexes do not 
typically exhibit the same reactivity profile as that of the diiron proteins [35, 130].  It is unlikely 
that every element of a protein active site, including the second coordination sphere, can be 
reproduced in a single model system.  But given the extent of the synthetic methodologies 
available today, it should be possible to overcome many of the obstacles that have impeded the 
development of more sophisticated diiron protein mimics [32]. 
Extensive reactivity studies utilizing molecular oxygen, hydrogen peroxide, alkyl 
peroxides, and oxygen atom transfer reagents with diiron model compounds have led to a much 
improved understanding of the oxidation chemistry that takes place in the active sites of 
carboxylate-bridged diiron proteins [32, 36].  For example, characterization of diiron(III,IV) and 
diiron(IV,IV) species in synthetic models [131-134] has shed some light on similar high-valent 
states that are accessible within the diiron protein cores.  These achievements help us to 
formulate possible reaction schemes that reconcile the biochemical data [17, 18] with the 
proposed biological mechanisms suggested by theory [67, 68, 135, 136].  Beyond the O2 
activation step, some synthetic systems are even able to perform catalytic hydrocarbon oxidation 
[34, 137, 138].  Although these reactions are typically not as efficient as those catalyzed by the 
bacterial monooxygenases, they represent a good start.  The current challenge in diiron model 
chemistry is to achieve regio- and stereospecific oxidation of external substrates by non-“free 
radical” reaction pathways.  Use of the earth-abundant molecule dioxygen, rather than other 
more reactive but environmentally less friendly chemical oxidants, to facilitate this chemistry is 
the ultimate goal.  The tasks set forth for future researchers in biomimetic modeling are 
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numerous and complex, but the advances that have been made over the past thirty years promise 
a future that is full of many exciting discoveries.   
4. Table of Abbreviations 
2-Ph2P(O)py 2-pyridyldiphenylphosphine oxide 
2-Ph2Py 2-pyridyldiphenylphosphine 
3-Fpy 3-fluoropyridine 
4-tBupy 4-tert-butylpyridine 
4-CNpy 4-cyanopyridine 
[G3]CO2– third generation dendrimer appended terphenylcarboxylate 
[LMe,Ph]2– anion of bis(phenyl(p-cresol)pyridyl)diethynylbenzene 
Ar4-FPhCO2– 2,6-bis(p-fluorophenyl)benzoate 
ArtBuCO2– 2,6-bis(p-(tert-butyl)phenyl)benzoate 
ArTolCO2– 2,6-bis(p-tolyl)benzoate 
bdptz 1,4-bis(2,2ʹ -dipyridylmethyl)phthalazine 
BEPEAN 2,7-bis(bis(2-(2-(5-ethyl)pyridyl)ethyl)aminomethyl)-1,8-naphthyridine 
BIPhMe bis(1-methylimidazol-2-yl)phenylmethoxymethane 
BMMs bacterial multi-component monooxygenases  
BPEAN 2,7-bis(bis(2-(2-(5-methyl)pyridyl)ethyl)aminomethyl)-1,8-naphthyridine 
BPMAN 2,7-bis(bis(2-pyridylmethyl)aminomethyl)-1,8-naphthyridine 
bpy 2,2ʹ -bipyridine 
BXDK2– benzyl substituted variant of XDK2– 
CV cyclic voltammetry 
deoxyHr reduced form of hemerythrin, with no dioxygen bound 
DAFA2– 1,8-bis(dimethylaminomethylethynyl)-3,6-di(tert-butyl)fluorine-9-yl-acetate 
DFT density functional theory 
ET electron transfer 
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Et2BCQEBEt 
1,2-bis(3-ethynyl-8-carboxylatequinoline)-4,5-diethynylbenzene methyl 
ester 
EXAFS extended X-ray absorption fine structure 
Hr hemerythrin 
Im2DET bis(N-methylimidazole)diethynyltriptycene 
iPrCO2– isobutyrate 
Lut 2,6-lutidine 
MArTolCO22– 
1,3-bis(aminomethyl)-4,6-diisopropylbenzene linked 
bis(terphenylcarboxylate) 
Mes 2,4,6-trimethylphenyl 
MPDP2– m-phenylenedipropionate 
NADH the reduced form of nicotinamide adenine dinucleotide 
N-MeIm N-methylimidazole 
N,N-Bn2en N,N-dibenzylethylenediamine 
N-tBuIm N-tert-butylimidazole 
oxyHr dioxygen-bound form of hemerythrin 
PDK4– anion of α,α-5,15-bis(α-N-(Kemp’s triacid imido)-o-tolyl)-2,8,12,18-tetraethyl-3,7,13,17-tetramethylporphyrin 
PIC2DET bis(picolinic methyl ester)diethynyltriptycene 
PIM2– dibenzylether linked bis(3-(methylphenoxylimine)phenyl)sulfone 
Ph4DBA2– dibenzofuran-4,6-bis(diphenylacetate) 
PhCO2– benzoate 
PhCyCO2– 1-phenylcyclohexylcarboxylate 
PXDK2– propyl substituted varient of XDK2– 
py pyridine 
R2 ribonucleotide reductase subunit containing the diiron active site 
RNR ribonucleotide reductase 
sMMOH soluble methane monooxygenase hydroxylase 
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t-BuCH2CO2– 1-tert-butylacetate 
t-BuCO2– pivalate 
THF tetrahydrofuran 
TMEDA N,N,Nʹ ,Nʹ -tetramethylethylenediamine 
ToMOH toluene/o-xylene monooxygenase hydroxylase 
TP– hydrotris(pyrazolyl)borate 
XDK2– anion of m-xylenediamine bis(Kemp’s triacid)imide 
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Table 1. Various Ligands Employed to Prepare Diiron Protein Model Complexes. 
 
Ligand/ Example of Iron Complexa Desirable  Characteristics 
Undesirable  
Characteristics 
Reference  
No. 
Mononucleating, Polydentate N-Heterocyclic Ligands 
 
 
TP– 
 
 
[Fe2(O)(CH3CO2)2(TP)2] (1) 
 
 Forms stable 
tripodal chelate with 
iron 
 N-donors similar to 
histidine residues 
 Easy to synthesize 
 
 Capping unit 
restricts binding to 
the metal center 
 Does not enforce 
dinuclearity 
 
37-39, 41 
 
 
 
BIPhMe 
 
 
[Fe2(HCO2)4(BIPhMe)2] (3) 
 
 
 Contains biomimetic 
imidazole groups 
 Bidentate chelate 
allows assembly of 
asymmetric diiron 
unit with open sites 
 Easy to synthesize 
 
 
 Does not enforce 
dinuclearity  
 
42, 43 
Dicarboxylate Ligands 
 
 
 
MPDP2– 
 
[Fe2(O)(MPDP)(BIPhMe)2Cl2] 
(6) 
 
 Enables assembly of 
[FeIII2O] units that 
could not be 
accessed using 
simple carboxylates 
 
 Does not enforce 
dinuclearity 
 
44, 45 
 
 
 
XDK2– 
 
 
[Fe2(XDK)(CyPhCO2)2(Py)2] 
(9) 
 
 
 Supports a diiron 
core with open sites 
for substitution with 
external 
carboxylates and N-
donor ligands 
 Maintains a di-
nuclear structure 
upon reaction with 
dioxygen 
  
 Endo positioning of 
carboxylates may be 
too geometrically 
restrictive 
 Does not prevent 
polynuclear 
aggregation 
 
49-57  
 
 
 
Ph4DBA2– 
 
 
[Fe2(OH)(Ph4DBA)(TMEDA)2 
(CH3CN)]+ (10) 
 
 
 Supports an 
{FeII2(OH)} core with 
an open binding site 
for dioxygen 
 Stabilizes an 
oxygenated adduct 
to the diiron center 
 
 Does not prevent 
formation of 
tetranuclear 
complexes 
 
60, 61 
 
 
PDK4– 
 
[Fe3(PDK)(Lut)(Br)2(HBr)] (12) 
 
  
 Provides both 
porphyrin and non-
porphyrin binding 
sites 
 
 Does not prevent 
formation of polyiron 
clusters 
 Difficult to prepare 
in gram quantities 
 
62-64 
aThe donor atoms highlighted in red and marked with an asterisk(*) in the iron complexes (second column) are 
derived from the donor groups, also shown with an asterisk, of the featured ligand (first column). 
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Table 1. (Continued) 
Ligand/ Example of Iron Complexa Desirable  Characteristics 
Undesirable  
Characteristics 
Reference 
No. 
 
Terphenylcarboxylate Ligands 
 
 
 
 
ArTolCO2–  
[Fe2(ArTolCO2)4(4-tBupy)2] 
(14A) 
 
 
 Forms diiron 
complexes in the 
presence of Fe(II) 
salts and an 
appropriate base 
 Stabilizes high-
valent iron species 
 Easy to synthesize 
 
 The steric 
encumbrance of 
the 2,6-aryl 
groups restricts 
access to the 
diiron core 
 Does not 
prevent 
formation of 
polyiron species 
 
72-75,  
77-78, 
80-95  
Dinucleating Polynitrogen Ligands 
 
 
BPEAN 
 
 
 
 
[Fe2(OH)(BPEAN)(SO3CF3)]2+ 
(24) 
 
 Contains a “masked 
carboxylate” to 
bridge two metal 
centers 
 Stabilizes diiron 
species in multiple 
oxidation states 
 
 Nitrogen-rich, 
rather than 
carboxylate-rich 
 
 
99-102 
 
 
 
bdptz 
 
 
 
[Fe2(OH)(bdptz)(ArTolCO2) 
(SO3CF3)(CH3CN)]+ (28) 
 
 
 Forms very stable 
bimetallic 
compounds 
 
 
 
 Nitrogen-rich, 
rather than 
carboxylate-rich 
 
 
103, 104 
syn N-Donor Ligands 
 
 
Et2BCQEBEt 
 
 
 
 
[Fe2(ArTolCO2)3(Et2BCQEBEt)]+ 
(30) 
 
 Enforces the syn 
stereochemistry of 
nitrogen donors 
relative to the Fe–Fe 
vector 
 Accommodates 
binding of external 
carboxylates to the 
diiron core 
 
 Neutral oxygen 
donors, rather 
than anionic 
 Quinoline ester 
group does not 
sufficiently 
stabilize the iron 
centers 
 
 
105-110  
 
1 
 
DAFA– 
 
 
 
 
N.A. 
 
 Contains a bridging 
carboxylate unit in 
addition to two 
adjacent amine 
groups 
 
 Not sufficiently 
pre-organized, 
could not 
metallate with 
iron 
 No clear 
advantage over 
Et2BCQEBEt 
design 
 
 
111 
aThe donor atoms highlighted in red and marked with an asterisk(*) in the iron complexes (second column) are 
derived from the donor groups, also shown with an asterisk, of the featured ligand (first column). N.A. = not 
available. 
	   36 
Table 1. (Continued) 
Ligand/ Example of Iron Complexa Desirable  Characteristics 
Undesirable  
Characteristics 
Reference 
No. 
 
Macrocyclic Ligands 
 
 
MArTolCO22– 
 
 
 
 
 
N.A. 
 
 May help control the 
nuclearity of the 
resulting iron 
complex 
 
 Metallation of 
this ligand has 
not yet been 
successful  
 
115 
 
 
 
PIM2– 
 
 
 
[Fe2(ArTolCO2)2(PIM)] 
(34) 
 
 Supports a 
carboxylate-bridged 
diiron(II) unit 
 Maintains a 
dinuclear core upon 
reaction with O2 
 Can be sterically 
tuned without 
obstructing access 
to the metal binding 
pocket. 
 
 
 Does not 
prevent 
formation of 
tetrairon species 
 Phenolate and 
imine donors are 
not biomimetic 
 
116 
aThe donor atoms highlighted in red and marked with an asterisk(*) in the iron complexes (second column) are 
derived from the donor groups, also shown with an asterisk, of the featured ligand (first column). N.A. = not 
available. 
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Scheme 1. Dioxygen reactivity of hemerythrin (Hr, top), ribonucleotide reductase (RNR, 
middle), and soluble methane monooxygenase hydroxylase (sMMOH, bottom).  The active site 
structures of the proteins in various redox states are depicted.	  
 
Scheme 2. A proposed mechanism for the reaction of [FeII2(µ-ArTolCO2)4(4-tBupy)2] (14A) with 
O2 [74, 75]. The actual structure of the diiron(III,IV) species 16 has not yet been determined. 
 
Scheme 3. A cartoon depiction of a diiron(II) model complex (39) containing a more sterically-
hindering PIM2– ligand, where the dark wedges represent a bulky organic substituent.  Reaction 
of 39 with dioxygen may lead to a carboxylate shift and formation of a di(µ-hydroxo)diiron(III) 
product (40).  The steric repulsion between the bulky PIM2– substituents should prevent 
undesired formation of [FeIII4(µ-OH)6(bulky PIM)2(RCO2)2] (41) complexes. 
 
Chart 1. Tethered substrates that could be successfully oxidized with O2 when integrated into a 
diiron(II) terphenylcarboxylate complex.  The starting substrate is depicted on top and the 
product isolated after oxygenation is shown directly below. 
 
Chart 2. Examples of crystallographically characterized [FeII2(syn N-donor)2] species isolated 
from reaction of iron(II) salts and the corresponding syn N-donor ligand. Additional external 
carboxylate ligands were used in the preparation in some cases. PIC2DET = bis(picolinic methyl 
ester)diethynyltriptycene [106]; Im2DET = bis(N-methylimidazole)diethynyltriptycene [106]; 
[LMe,Ph]2– = bis(phenyl(p-cresol)pyridyl)diethynylbenzene [110]; ArTolCO2– = 2,6-di(p-
tolyl)benzoate. 
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Scheme 1. 
	   39 
 
Scheme 2. 
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Scheme 3. 
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Chart 1. 
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Chart 2. 
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